QGENQiagen N.V.
Is the price fair?
Growth expectations in line with delivery. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~4% a year FCF growth. Moderate growth expectations are priced in.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What QGEN's price assumes
Qiagen N.V. trades at 23.4× earnings against 35.2× for the median Diagnostics & Research name, cheaper than its own group.
Trailing P/E · Diagnostics & Research median 35.2 · cheaper than the typical name in its group
- Price / sales
- 1.20
Price / sales · as of 2025-FY
- Free cash flow yield
- 5.6%
Free cash flow yield · Diagnostics & Research median 3.7%
- Growth the price implies
- +4.0%
Growth the price implies · The price pays for +4.0% free cash flow growth a year for a decade; the business has delivered −8.2% a year over the last three.
Details›
- Price / bookas of 2025-FY
- 2.61
- EV / EBITas of 2025-FY
- 7.08
- EV / salesas of 2025-FY
- 1.30
- Healthcare median P/E509 names
- 26.2
- Diagnostics & Research median P/E33 names
- 35.2
- Free cash flow, trailing twelve months
- $453M
- Market capitalisation
- $8.03B
- 3-year revenue growth
- −0.81%
- 3-year free cash flow growth
- −8.2%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #2 of 21 by RyuScore